Faron Pharmaceuticals Oy (4FR) Stock Price & Analysis
4FR Stock Chart & Stats
- Day’s Range
- EUR 0.37 - EUR 0.37
- 52-Week Range
- EUR 0.36 - EUR 2.27
- Previous Close
- EUR 0.37
- Volume
- N/A
- Average Volume (3M)
- 225
- Market Cap
- EUR 75.07M
- Enterprise Value
- EUR 60.49M
- Total Cash (Recent Filing)
- N/A
- Total Debt (Recent Filing)
- EUR 2.36M
- Price to Earnings (P/E)
- ―
- Beta
- 0.04
- Next Earnings
- Mar 19, 2027 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Faron Pharmaceuticals Oy News
4FR FAQ
What was Faron Pharmaceuticals Oy’s price range in the past 12 months?
What is Faron Pharmaceuticals Oy’s market cap?
When is Faron Pharmaceuticals Oy’s upcoming earnings report date?
How were Faron Pharmaceuticals Oy’s earnings last quarter?
Is Faron Pharmaceuticals Oy overvalued?
Does Faron Pharmaceuticals Oy pay dividends?
What is Faron Pharmaceuticals Oy’s EPS estimate?
How many shares outstanding does Faron Pharmaceuticals Oy have?
What happened to Faron Pharmaceuticals Oy’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Faron Pharmaceuticals Oy?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies. The company also develops Haematokine, a new chemical entity AOC3 inhibitor for the treatment of hematological malignancies and bone marrow. Faron Pharmaceuticals Oy was founded in 2003 and is headquartered in Turku, Finland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Juho Markku Jalkanen M.D., MSc, Ph.D.
- Employees
- 25
- Website
- www.faron.com
- Address
- Joukahaisenkatu 6 B, Turku, 20520, FI
Faron Pharmaceuticals Oy (4FR) Earnings & Revenues
4FR Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 7 | 3 | 12 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 2 | 0 | 10 |
